<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>SUNMO Trial Primary Results</title>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.11.5/gsap.min.js"></script>
    <link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet">
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Lato:wght@300;400;700;900&display=swap');

        :root {
            --jnj-blue-dark: #003366;
            --jnj-blue-medium: #006699;
            --jnj-blue-light: #00AEEF;
            --mosun-pola-green: #2E8B57; /* SeaGreen */
            --rgemox-blue: #4682B4; /* SteelBlue */
            --text-dark: #222222;
            --text-light: #555555;
            --background-light: #f8f9fa;
            --background-white: #ffffff;
            --border-color: #dee2e6;
        }

        body {
            font-family: 'Lato', sans-serif;
            color: var(--text-dark);
            margin: 0;
            padding: 0;
            background-color: var(--background-light);
            overflow-x: hidden;
        }

        .container {
            width: 90%;
            max-width: 1200px;
            margin: 0 auto;
            padding: 40px 0;
        }

        header {
            background: var(--jnj-blue-dark);
            color: var(--background-white);
            padding: 30px 0;
            text-align: center;
        }

        header h1 {
            font-size: 2.8rem;
            margin: 0 0 10px 0;
            font-weight: 700;
        }

        header p {
            font-size: 1.2rem;
            margin: 0;
            font-weight: 300;
        }

        .card {
            background: var(--background-white);
            border-radius: 8px;
            box-shadow: 0 4px 12px rgba(0,0,0,0.05);
            padding: 30px;
            margin-bottom: 40px;
        }

        h2 {
            font-size: 2.2rem;
            color: var(--jnj-blue-dark);
            border-bottom: 3px solid var(--jnj-blue-light);
            padding-bottom: 10px;
            margin-top: 0;
            margin-bottom: 25px;
            font-weight: 700;
        }

        h3 {
            font-size: 1.6rem;
            color: var(--jnj-blue-medium);
            margin-top: 0;
            margin-bottom: 20px;
            font-weight: 700;
        }
        
        .plain-language-summary {
            background-color: #e7f3fe;
            border-left: 5px solid var(--jnj-blue-light);
            padding: 20px;
            margin-bottom: 30px;
        }

        .plain-language-summary p {
            font-size: 1.1rem;
            color: var(--text-dark);
            margin: 0;
        }

        .executive-summary {
            display: flex;
            justify-content: space-around;
            text-align: center;
            padding: 20px 0;
        }

        .stat-item {
            flex-basis: 30%;
        }

        .stat-item .stat-number {
            font-size: 4rem;
            font-weight: 900;
            color: var(--jnj-blue-dark);
        }

        .stat-item .stat-label {
            font-size: 1.1rem;
            color: var(--text-light);
        }
        
        .grid-2-col {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 30px;
        }

        .study-design-container {
            display: flex;
            flex-direction: column;
            align-items: center;
        }
        
        .study-design-box {
            border: 2px solid var(--border-color);
            border-radius: 8px;
            padding: 15px;
            text-align: center;
            width: 80%;
            margin-bottom: 15px;
            background: #f8f9fa;
        }
        .study-design-box h4 { margin: 0 0 5px 0; color: var(--jnj-blue-dark); }
        .study-design-box p { margin: 0; font-size: 0.9rem; }
        
        .arrow {
            font-size: 2rem;
            color: var(--jnj-blue-medium);
            margin-bottom: 15px;
        }
        
        .treatment-arms {
            display: flex;
            justify-content: space-around;
            width: 100%;
        }
        
        .arm {
            width: 45%;
            padding: 15px;
            border-radius: 8px;
            text-align: center;
        }
        .arm-a { border: 2px solid var(--mosun-pola-green); }
        .arm-b { border: 2px solid var(--rgemox-blue); }
        .arm h4 { margin: 0 0 10px 0; }
        .arm p { font-size: 0.9rem; margin: 0; }
        .arm-a h4 { color: var(--mosun-pola-green); }
        .arm-b h4 { color: var(--rgemox-blue); }
        
        .vs-circle {
            align-self: center;
            font-size: 1.2rem;
            font-weight: 700;
            color: var(--jnj-blue-dark);
        }
        
        .baseline-table {
            width: 100%;
            border-collapse: collapse;
        }
        .baseline-table th, .baseline-table td {
            padding: 12px;
            border-bottom: 1px solid var(--border-color);
            text-align: left;
        }
        .baseline-table th {
            background: #f2f2f2;
            font-weight: 700;
            text-align: center;
        }
        .baseline-table td:first-child { font-weight: 700; color: var(--text-light); }
        .baseline-table td { text-align: center; }
        .baseline-table .header-green { color: var(--mosun-pola-green); }
        .baseline-table .header-blue { color: var(--rgemox-blue); }

        .chart-container {
            position: relative;
            width: 100%;
        }
        .tooltip {
            position: absolute;
            text-align: center;
            width: auto;
            padding: 8px;
            font: 12px sans-serif;
            background: lightsteelblue;
            border: 0px;
            border-radius: 8px;
            pointer-events: none;
            opacity: 0;
        }
        .axis path, .axis line {
            fill: none;
            stroke: var(--text-dark);
            shape-rendering: crispEdges;
        }
        .axis text {
            font-size: 12px;
            fill: var(--text-dark);
        }
        .legend {
            display: flex;
            justify-content: center;
            margin-top: 20px;
        }
        .legend-item {
            display: flex;
            align-items: center;
            margin: 0 15px;
        }
        .legend-color {
            width: 20px;
            height: 10px;
            margin-right: 8px;
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
        }
        
        .safety-card {
            border: 1px solid var(--border-color);
            border-radius: 8px;
            padding: 20px;
        }
        
        .safety-card h4 {
            color: var(--jnj-blue-medium);
            margin-top: 0;
            font-size: 1.2rem;
        }
        
        .crs-card {
            background-color: #e6f3ee;
            border-left: 5px solid var(--mosun-pola-green);
        }

        .conclusion-list {
            list-style: none;
            padding-left: 0;
        }

        .conclusion-list li {
            padding: 10px 0 10px 30px;
            position: relative;
            font-size: 1.1rem;
            line-height: 1.6;
        }
        
        .conclusion-list li::before {
            content: '✓';
            color: var(--mosun-pola-green);
            position: absolute;
            left: 0;
            top: 10px;
            font-weight: bold;
            font-size: 1.4rem;
        }
        
        footer {
            background: var(--jnj-blue-dark);
            color: #ccc;
            padding: 40px 0;
            font-size: 0.8rem;
        }
        
        footer h3 {
            color: var(--background-white);
            font-size: 1.2rem;
            border-bottom: 1px solid var(--jnj-blue-medium);
            padding-bottom: 8px;
        }
        footer .grid-2-col {
            gap: 50px;
        }
        footer p, footer ul {
            margin: 0;
            padding: 0;
            line-height: 1.6;
        }
        footer ul { list-style: none; }
        footer a { color: var(--jnj-blue-light); text-decoration: none; }
        footer a:hover { text-decoration: underline; }

        @media (max-width: 768px) {
            .grid-2-col, .executive-summary, .treatment-arms {
                grid-template-columns: 1fr;
                flex-direction: column;
            }
            header h1 { font-size: 2rem; }
            h2 { font-size: 1.8rem; }
            .stat-item { margin-bottom: 20px; }
            .arm { width: 100%; margin-bottom: 10px; }
        }

    </style>
</head>
<body>

    <header>
        <div data-aos="fade-down">
            <h1>SUNMO: Primary Results of the Phase III Trial</h1>
            <p>Mosunetuzumab + Polatuzumab Vedotin vs. R-GemOx in Transplant-Ineligible R/R Large B-cell Lymphoma</p>
            <p style="font-size: 0.9rem; margin-top: 10px;">Presented by Dr. Jason Westin at the 18th ICML, June 17-21, 2025</p>
        </div>
    </header>

    <div class="container">
        <section class="card" data-aos="fade-up">
            <h2>Executive Summary</h2>
            <div class="plain-language-summary">
                <p><strong>In plain language:</strong> For patients with relapsed or refractory (R/R) large B-cell lymphoma who are not eligible for a transplant, this study tested a new, chemotherapy-free combination treatment. The results show this new combination (Mosun-Pola) was significantly more effective at controlling the cancer and preventing it from worsening compared to the standard chemotherapy regimen (R-GemOx).</p>
            </div>
            <div class="executive-summary">
                <div class="stat-item" data-aos="zoom-in" data-aos-delay="100">
                    <span class="stat-number" id="stat1">0</span>%
                    <div class="stat-label">Reduction in risk of progression or death (HR: 0.41)</div>
                </div>
                <div class="stat-item" data-aos="zoom-in" data-aos-delay="200">
                    <span class="stat-number" id="stat2">0</span>x
                    <div class="stat-label">Increase in median Progression-Free Survival (11.5 vs 3.8 months)</div>
                </div>
                <div class="stat-item" data-aos="zoom-in" data-aos-delay="300">
                    <span class="stat-number" id="stat3">0</span>x
                    <div class="stat-label">The Complete Response rate (51.4% vs 24.3%)</div>
                </div>
            </div>
        </section>

        <section class="card" data-aos="fade-up">
            <h2>Study Design (NCT05171647)</h2>
            <div class="study-design-container" id="study-design-flow">
                <div class="study-design-box" data-aos="fade-down">
                    <h4>Key Eligibility</h4>
                    <p>Patients with R/R LBCL after ≥1 prior therapy, ineligible for Autologous Stem Cell Transplant (ASCT)</p>
                </div>
                <div class="arrow" data-aos="fade-down">↓</div>
                <div class="study-design-box" data-aos="fade-down">
                     <h4>Stratification Factors</h4>
                    <p>1 vs ≥2 prior lines of therapy | Relapsed vs. Refractory disease</p>
                </div>
                <div class="arrow" data-aos="fade-down">↓</div>
                 <div class="study-design-box" data-aos="fade-down" style="width: 30%;">
                    <h4>Randomization (2:1)</h4>
                </div>
                <div class="treatment-arms">
                    <div class="arm arm-a" data-aos="fade-right">
                        <h4>Mosun-Pola Arm (n=138)</h4>
                        <p>Outpatient Mosunetuzumab SC + Polatuzumab Vedotin IV for a fixed duration</p>
                    </div>
                    <div class="vs-circle" data-aos="zoom-in">VS</div>
                    <div class="arm arm-b" data-aos="fade-left">
                        <h4>R-GemOx Arm (n=70)</h4>
                        <p>Rituximab + Gemcitabine and Oxaliplatin IV</p>
                    </div>
                </div>
                 <div class="arrow" data-aos="fade-up">↓</div>
                 <div class="study-design-box" data-aos="fade-up">
                    <h4>Dual Primary Endpoints</h4>
                    <p>Progression-Free Survival (PFS) & Objective Response Rate (ORR) by Independent Review Committee (IRC)</p>
                </div>
            </div>
        </section>

        <section class="card" data-aos="fade-up">
            <h2>Baseline Patient Characteristics</h2>
             <table class="baseline-table">
                <thead>
                    <tr>
                        <th>Characteristic</th>
                        <th class="header-green">Mosun-Pola (n=138)</th>
                        <th class="header-blue">R-GemOx (n=70)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Median Age, years (range)</td>
                        <td>62 (23-87)</td>
                        <td>63 (29-85)</td>
                    </tr>
                    <tr>
                        <td>Male Sex, %</td>
                        <td>55.1%</td>
                        <td>64.3%</td>
                    </tr>
                     <tr>
                        <td>ECOG Performance Status 2, %</td>
                        <td>13.0%</td>
                        <td>1.4%</td>
                    </tr>
                    <tr>
                        <td>NHL Subtype: DLBCL, %</td>
                        <td>79.0%</td>
                        <td>77.1%</td>
                    </tr>
                    <tr>
                        <td>Median Prior Lines of Therapy (range)</td>
                        <td>2 (1-9)</td>
                        <td>2 (1-5)</td>
                    </tr>
                    <tr>
                        <td>Refractory to last therapy, %</td>
                        <td>70.3%</td>
                        <td>68.6%</td>
                    </tr>
                </tbody>
            </table>
        </section>
        
        <section class="card" data-aos="fade-up">
            <h2>Efficacy: Superior Outcomes with Mosun-Pola</h2>
            <div class="grid-2-col">
                <div data-aos="fade-right">
                    <h3>Progression-Free Survival (PFS) by IRC</h3>
                    <div id="pfs-chart" class="chart-container"></div>
                    <div class="legend">
                        <div class="legend-item"><div class="legend-color" style="background-color: var(--mosun-pola-green);"></div> Mosun-Pola</div>
                        <div class="legend-item"><div class="legend-color" style="background-color: var(--rgemox-blue); border-style: dashed; border-width: 2px; height: 6px;"></div> R-GemOx</div>
                    </div>
                    <p style="text-align:center; font-weight: bold; margin-top: 15px;">Median PFS: 11.5 months vs. 3.8 months<br>HR 0.41 (95% CI: 0.28-0.61); p < 0.0001</p>
                </div>
                <div data-aos="fade-left">
                    <h3>Overall and Complete Response Rates (ORR & CR)</h3>
                     <div id="orr-chart" class="chart-container"></div>
                     <p style="text-align:center; font-weight: bold; margin-top: 15px;">Mosun-Pola doubled the complete response rate.</p>
                </div>
            </div>
             <div class="grid-2-col" style="margin-top: 40px;">
                <div data-aos="fade-right">
                    <h3>Duration of Complete Response (DOCR)</h3>
                    <div id="docr-chart" class="chart-container"></div>
                    <div class="legend">
                        <div class="legend-item"><div class="legend-color" style="background-color: var(--mosun-pola-green);"></div> Mosun-Pola</div>
                        <div class="legend-item"><div class="legend-color" style="background-color: var(--rgemox-blue); border-style: dashed; border-width: 2px; height: 6px;"></div> R-GemOx</div>
                    </div>
                    <p style="text-align:center; font-weight: bold; margin-top: 15px;">12-Month DOCR: 72.6% vs. 44.1%</p>
                </div>
                <div data-aos="fade-left">
                    <h3>Overall Survival (OS) - Interim Analysis</h3>
                    <div id="os-chart" class="chart-container"></div>
                    <div class="legend">
                        <div class="legend-item"><div class="legend-color" style="background-color: var(--mosun-pola-green);"></div> Mosun-Pola</div>
                        <div class="legend-item"><div class="legend-color" style="background-color: var(--rgemox-blue); border-style: dashed; border-width: 2px; height: 6px;"></div> R-GemOx</div>
                    </div>
                    <p style="text-align:center; font-weight: bold; margin-top: 15px;">Median OS: 18.7 months vs. 13.6 months<br>HR 0.80 (95% CI: 0.54-1.20); p=0.2835</p>
                </div>
            </div>
        </section>

        <section class="card" data-aos="fade-up">
            <h2>Manageable Safety Profile</h2>
            <p>Adverse event (AE) rates were generally comparable between arms, with fewer AEs leading to treatment discontinuation in the Mosun-Pola arm (2.2% vs. 4.7%).</p>
            <div class="safety-grid">
                <div class="safety-card" data-aos="fade-up">
                    <h4>Key Adverse Events</h4>
                    <div id="ae-chart"></div>
                </div>
                <div class="safety-card crs-card" data-aos="fade-up" data-aos-delay="100">
                    <h4>Spotlight on Cytokine Release Syndrome (CRS)</h4>
                    <p>CRS was infrequent, occurred early, and was low-grade with Mosun-Pola.</p>
                    <ul>
                        <li><strong>Any Grade CRS:</strong> 25.9%</li>
                        <li><strong>Grade 1:</strong> 21.5%</li>
                        <li><strong>Grade 2:</strong> 3.7%</li>
                        <li><strong>Grade ≥3:</strong> 0.7% (1 patient)</li>
                        <li><strong>Key finding:</strong> 96% of patients had no significant (Grade ≥2) CRS, facilitating outpatient administration.</li>
                    </ul>
                </div>
                <div class="safety-card" data-aos="fade-up" data-aos-delay="200">
                     <h4>Other AEs of Interest (Mosun-Pola vs R-GemOx)</h4>
                    <ul>
                        <li><strong>Peripheral Neuropathy:</strong> 24.4% vs 42.2%</li>
                        <li><strong>Infections (Grade ≥3):</strong> 15.6% vs 14.1%</li>
                        <li><strong>Neutropenia (Grade ≥3):</strong> 33.3% vs 31.3%</li>
                        <li><strong>Febrile Neutropenia:</strong> 2.2% vs 3.1%</li>
                        <li><strong>Immune Effector Cell-Associated Neurotoxicity (ICANS):</strong> 0 cases observed</li>
                    </ul>
                </div>
            </div>
        </section>

        <section class="card" data-aos="fade-up">
            <h2>Conclusions</h2>
            <ul class="conclusion-list">
                <li data-aos="fade-left">SUNMO is the first positive Phase III trial of a chemotherapy-free regimen for transplant-ineligible R/R LBCL patients.</li>
                <li data-aos="fade-left" data-aos-delay="100">Mosun-Pola provided clinically meaningful and statistically significant improvements in PFS, ORR, and CR rate.</li>
                <li data-aos="fade-left" data-aos-delay="200">Mosun-Pola demonstrated a 59% reduction in the risk of progression or death compared with standard chemotherapy.</li>
                <li data-aos="fade-left" data-aos-delay="300">The safety profile was manageable and consistent with known risks, with a notably low incidence of significant CRS, making it suitable for broad outpatient use.</li>
                <li data-aos="fade-left" data-aos-delay="400">Mosun-Pola represents a potential new standard of care for this patient population with a high unmet need.</li>
            </ul>
        </section>

    </div>

    <footer>
        <div class="container">
            <div class="grid-2-col">
                <div>
                    <h3>Abbreviations</h3>
                    <p>
                        <strong>AE:</strong> Adverse Event; <strong>ASCT:</strong> Autologous Stem Cell Transplant; <strong>CI:</strong> Confidence Interval; <strong>CR:</strong> Complete Response; <strong>CRS:</strong> Cytokine Release Syndrome; <strong>DLBCL:</strong> Diffuse Large B-cell Lymphoma; <strong>DOCR:</strong> Duration of Complete Response; <strong>HR:</strong> Hazard Ratio; <strong>ICANS:</strong> Immune Effector Cell-Associated Neurotoxicity Syndrome; <strong>IRC:</strong> Independent Review Committee; <strong>LBCL:</strong> Large B-cell Lymphoma; <strong>Mosun-Pola:</strong> Mosunetuzumab plus Polatuzumab Vedotin; <strong>ORR:</strong> Objective Response Rate; <strong>OS:</strong> Overall Survival; <strong>PFS:</strong> Progression-Free Survival; <strong>R-GemOx:</strong> Rituximab, Gemcitabine, and Oxaliplatin; <strong>R/R:</strong> Relapsed/Refractory.
                    </p>
                </div>
                <div>
                    <h3>Disclosures & References</h3>
                    <p>
                        <strong>Clinical Trial Information:</strong> NCT05171647. <br>
                        <strong>Clinical Cut-off Date:</strong> 17 February, 2025. <br>
                        <strong>Sponsor:</strong> F. Hoffmann-La Roche Ltd. <br>
                        Third-party medical writing assistance was funded by F. Hoffmann-La Roche Ltd.
                    </p>
                    <h3 style="margin-top:20px;">References</h3>
                    <ul>
                        <li>1. Sun LL, et al. Sci Transl Med 2015;7:287ra70.</li>
                        <li>2. Dornan D, et al. Blood 2009;114:2721-9.</li>
                        <li>3. Budde LE, et al. Nat Med 2024;30:229-39.</li>
                        <li>4. Chavez JC, et al. ASH 2024, oral presentation #989.</li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

    <script>
        AOS.init({
            duration: 800,
            once: true
        });
        
        // GSAP Animations
        gsap.to("#stat1", { innerText: 59, duration: 2, snap: "innerText" });
        gsap.to("#stat2", { innerText: 3, duration: 2, snap: "innerText" });
        gsap.to("#stat3", { innerText: 2, duration: 2, snap: "innerText" });

        // D3.js Charts
        
        // Tooltip
        const tooltip = d3.select("body").append("div")
            .attr("class", "tooltip");

        // --- PFS Chart ---
        const pfsData = [
            { arm: 'mp', time: 0, val: 100 }, { arm: 'mp', time: 3, val: 82 }, { arm: 'mp', time: 6, val: 60 }, { arm: 'mp', time: 9, val: 55 }, { arm: 'mp', time: 12, val: 49 }, { arm: 'mp', time: 18, val: 40 }, { arm: 'mp', time: 24, val: 35 }, { arm: 'mp', time: 30, val: 35 },
            { arm: 'rg', time: 0, val: 100 }, { arm: 'rg', time: 3, val: 45 }, { arm: 'rg', time: 6, val: 28 }, { arm: 'rg', time: 9, val: 20 }, { arm: 'rg', time: 12, val: 15 }, { arm: 'rg', time: 18, val: 14 }, { arm: 'rg', time: 24, val: 10 }, { arm: 'rg', time: 27, val: 0 }
        ];
        createKMCurve("#pfs-chart", pfsData, 30);
        
        // --- DOCR Chart ---
        const docrData = [
             { arm: 'mp', time: 0, val: 100 }, { arm: 'mp', time: 3, val: 95 }, { arm: 'mp', time: 6, val: 85 }, { arm: 'mp', time: 9, val: 78 }, { arm: 'mp', time: 12, val: 72.6 }, { arm: 'mp', time: 18, val: 62 }, { arm: 'mp', time: 24, val: 56 }, { arm: 'mp', time: 27, val: 56 },
             { arm: 'rg', time: 0, val: 100 }, { arm: 'rg', time: 3, val: 85 }, { arm: 'rg', time: 6, val: 65 }, { arm: 'rg', time: 9, val: 55 }, { arm: 'rg', time: 12, val: 44.1 }, { arm: 'rg', time: 18, val: 43 }, { arm: 'rg', time: 21, val: 0 }
        ];
        createKMCurve("#docr-chart", docrData, 30);
        
        // --- OS Chart ---
        const osData = [
            { arm: 'mp', time: 0, val: 100 }, { arm: 'mp', time: 6, val: 88 }, { arm: 'mp', time: 12, val: 61.4 }, { arm: 'mp', time: 18, val: 49 }, { arm: 'mp', time: 24, val: 46 }, { arm: 'mp', time: 30, val: 45 }, { arm: 'mp', time: 33, val: 45 },
            { arm: 'rg', time: 0, val: 100 }, { arm: 'rg', time: 6, val: 78 }, { arm: 'rg', time: 12, val: 53.4 }, { arm: 'rg', time: 18, val: 42 }, { arm: 'rg', time: 24, val: 38 }, { arm: 'rg', time: 30, val: 36 }
        ];
        createKMCurve("#os-chart", osData, 33);
        
        function createKMCurve(containerId, data, maxTime) {
            const margin = {top: 20, right: 30, bottom: 50, left: 50},
                  width = 500 - margin.left - margin.right,
                  height = 350 - margin.top - margin.bottom;

            const svg = d3.select(containerId)
              .append("svg")
                .attr("viewBox", `0 0 ${width + margin.left + margin.right} ${height + margin.top + margin.bottom}`)
              .append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);
            
            const x = d3.scaleLinear().domain([0, maxTime]).range([0, width]);
            svg.append("g")
                .attr("transform", `translate(0, ${height})`)
                .call(d3.axisBottom(x))
                .append("text")
                .attr("y", 40)
                .attr("x", width/2)
                .attr("text-anchor", "middle")
                .attr("fill", "black")
                .attr("font-weight", "bold")
                .text("Time (months)");

            const y = d3.scaleLinear().domain([0, 100]).range([height, 0]);
            svg.append("g")
                .call(d3.axisLeft(y).ticks(5))
                .append("text")
                .attr("transform", "rotate(-90)")
                .attr("y", -40)
                .attr("x", -height/2)
                .attr("text-anchor", "middle")
                .attr("fill", "black")
                .attr("font-weight", "bold")
                .text("Probability (%)");
            
            const line = d3.line()
                .x(d => x(d.time))
                .y(d => y(d.val))
                .curve(d3.curveStepAfter);

            const mp_data = data.filter(d => d.arm === 'mp');
            svg.append("path")
              .datum(mp_data)
              .attr("fill", "none")
              .attr("stroke", "var(--mosun-pola-green)")
              .attr("stroke-width", 2.5)
              .attr("d", line);

            const rg_data = data.filter(d => d.arm === 'rg');
            svg.append("path")
              .datum(rg_data)
              .attr("fill", "none")
              .attr("stroke", "var(--rgemox-blue)")
              .attr("stroke-width", 2.5)
              .attr("stroke-dasharray", ("5, 5"))
              .attr("d", line);
        }
        
        // --- ORR Chart ---
        const orrData = [
            { group: "Mosun-Pola (n=138)", cr: 51.4, pr: 18.9, total: 70.3 },
            { group: "R-GemOx (n=70)", cr: 24.3, pr: 15.7, total: 40.0 }
        ];
        const orrMargin = {top: 20, right: 30, bottom: 40, left: 60},
              orrWidth = 500 - orrMargin.left - orrMargin.right,
              orrHeight = 350 - orrMargin.top - orrMargin.bottom;

        const orrSvg = d3.select("#orr-chart")
            .append("svg")
            .attr("viewBox", `0 0 ${orrWidth + orrMargin.left + orrMargin.right} ${orrHeight + orrMargin.top + orrMargin.bottom}`)
            .append("g")
            .attr("transform", `translate(${orrMargin.left},${orrMargin.top})`);
            
        const orrX = d3.scaleBand()
          .range([ 0, orrWidth ])
          .domain(orrData.map(d => d.group))
          .padding(0.2);
        orrSvg.append("g")
          .attr("transform", "translate(0," + orrHeight + ")")
          .call(d3.axisBottom(orrX));

        const orrY = d3.scaleLinear()
          .domain([0, 80])
          .range([ orrHeight, 0]);
        orrSvg.append("g")
          .call(d3.axisLeft(orrY).ticks(4))
          .append("text")
            .attr("transform", "rotate(-90)")
            .attr("y", -45)
            .attr("x", -orrHeight/2)
            .attr("text-anchor", "middle")
            .attr("fill", "black")
            .attr("font-weight", "bold")
            .text("Response Rate (%)");
        
        const stackedData = d3.stack().keys(["cr", "pr"])(orrData);
        
        orrSvg.append("g")
            .selectAll("g")
            .data(stackedData)
            .enter().append("g")
            .attr("fill", d => d.key === 'cr' ? 'var(--jnj-blue-dark)' : 'var(--jnj-blue-light)')
            .selectAll("rect")
            .data(d => d)
            .enter().append("rect")
            .attr("x", d => orrX(d.data.group))
            .attr("y", d => orrY(d[1]))
            .attr("height", d => orrY(d[0]) - orrY(d[1]))
            .attr("width", orrX.bandwidth());
            
        // --- AE Chart ---
        const aeData = [
            {ae: "Thrombocytopenia", mp: 30, rg: 55},
            {ae: "Neutropenia", mp: 46, rg: 55},
            {ae: "Anemia", mp: 25, rg: 45},
            {ae: "Peripheral Neuropathy", mp: 24, rg: 42},
            {ae: "Injection Site Reaction", mp: 53, rg: 0},
            {ae: "CRS", mp: 26, rg: 0},
        ].reverse();
        
        const aeMargin = {top: 20, right: 20, bottom: 20, left: 140},
              aeWidth = 400 - aeMargin.left - aeMargin.right,
              aeHeight = 250 - aeMargin.top - aeMargin.bottom;
              
        const aeSvg = d3.select("#ae-chart")
            .append("svg")
            .attr("viewBox", `0 0 ${aeWidth + aeMargin.left + aeMargin.right} ${aeHeight + aeMargin.top + aeMargin.bottom}`);
            
        const aeY = d3.scaleBand()
            .range([0, aeHeight])
            .domain(aeData.map(d => d.ae))
            .padding(0.3);
            
        const aeX = d3.scaleLinear()
            .domain([0, 60])
            .range([0, aeWidth]);

        const g = aeSvg.append("g").attr("transform", `translate(${aeMargin.left},${aeMargin.top})`);
        
        g.append("g")
         .call(d3.axisLeft(aeY).tickSize(0))
         .select(".domain").remove();
         
        g.selectAll(".bar-mp")
         .data(aeData)
         .enter().append("rect")
         .attr("class", "bar-mp")
         .attr("y", d => aeY(d.ae))
         .attr("height", aeY.bandwidth()/2)
         .attr("x", 0)
         .attr("width", d => aeX(d.mp))
         .attr("fill", "var(--mosun-pola-green)");
         
        g.selectAll(".bar-rg")
         .data(aeData)
         .enter().append("rect")
         .attr("class", "bar-rg")
         .attr("y", d => aeY(d.ae) + aeY.bandwidth()/2)
         .attr("height", aeY.bandwidth()/2)
         .attr("x", 0)
         .attr("width", d => aeX(d.rg))
         .attr("fill", "var(--rgemox-blue)");
    </script>

</body>
</html>